The breadth of AI in healthcare applications is broad. How much human oversight is necessary or preferred when leveraging AI in the interest of patient safety?

Listen to this in-depth discussion on how AI can help identify end-to-end data weaknesses, as well as broader implications regarding the inevitability of human interaction.

This is part two of a discussion focused upon data bias, accuracy, access and the future of AI in drug development.

Host 

⁠Lori Ellis⁠, Head of Insights, BioSpace  

Guests 

⁠Paul Agapow⁠, Director of Innovation, Data Science and Strategy, GlaxoSmithKline⁠

Mike King⁠, Senior Director of Product and Strategy, IQVIA 

⁠Nindhana Paranthaman⁠, Executive Medical Director, Exelixis 

⁠Moritz von Stosch⁠, Chief Information Officer, DataHow